Potential new therapy of Rapalink‐1, a new generation mammalian target of rapamycin inhibitor, against sunitinib‐resistant renal cell carcinoma-Reference-Cited by-同舟云学术

Potential new therapy of Rapalink‐1, a new generation mammalian target of rapamycin inhibitor, against sunitinib‐resistant renal cell carcinoma

Published:2020-05 Issue:5 Volume:111 Page:1607-1618
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Kuroshima Kazuki¹,Yoshino Hirofumi¹,Okamura Shunsuke¹,Tsuruda Masafumi¹,Osako Yoichi¹,Sakaguchi Takashi¹,Sugita Satoshi¹,Tatarano Shuichi¹,Nakagawa Masayuki¹,Enokida Hideki¹^ORCID

Affiliation:

1. Department of Urology Graduate School of Medical and Dental Sciences Kagoshima University Kagoshima Japan

Funder

the KAKENHI

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14395

Reference49 articles.

1. Renal cancer

2. Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies

3. International Consultation on Urologic Diseases and the European Association of Urology International Consultation on Locally Advanced Renal Cell Carcinoma

4. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma

5. PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Autophagy modulation in cancer therapy: Challenges coexist with opportunities;European Journal of Medicinal Chemistry;2024-10

2. Rapalink-1 reveals novel mTOR-dependent genes and an agmatinergic axis-based metabolic feedback regulating mTOR activity and lifespan;2024-07-22

3. Integrated analysis of differentially m6A modified and expressed lncRNAs for biomarker identification in coronary artery disease;Cell Biology International;2024-07-14

4. Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer;Cancers;2024-06-18

5. Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in NF2-deficient models;Neuro-Oncology Advances;2024-01-01